Hansa Medical Nears Market With IdeS For Sensitized Transplant Patients
Executive Summary
A product derived from a bacterial protein, IdeS, could be the first medicine from Sweden's Hansa Medical to tackle a serious unmet need, transplant patients unable to find a donor match because of HLA sensitization.